SENSEI BIOTHERAPEUTICS INC
Sensei Biotherapeutics, Inc. is an immuno-oncology company focused on the discovery and development of therapeutics for cancer. The Company has designed two approaches to develop therapeutics its Tumor Microenvironment Activated biologics (TMAb) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage platform, which trains new T cells to recognize and kill malignant cells. Using its TMAb platform, the Company is developing SNS-101, human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment. The Company is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications. The Company has four investigational products in various stages of early development: SNS-101, SNS-102, SNS-103 and SNS-401.
Buy US stocks in Australia starting with SNSE. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in SNSE
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.